Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : US5324571083
Share Class Description:
LTS:0Q1G: Ordinary SharesTotal Employee Number:
50,000Compare
Compare
Traded in other countries / regions
LLY.USALLY.CanadaLILY34.BrazilLLY.ArgentinaLLY.GermanyLLY.Mexico1LLY.ItalyLLYC.AustriaLLYCL.ChileLLY.SwitzerlandLLY.BulgariaLILY.Poland0Q1G.UK IPO Date
2013-10-10Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 1.39 | |||||
Debt-to-EBITDA | 1.15 | |||||
Interest Coverage | 50.14 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 9.26 | |||||
Beneish M-Score | -1.67 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31.9 | |||||
3-Year EBITDA Growth Rate | 54.4 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 9.3 | |||||
3-Year Book Growth Rate | 38.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.42 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 4.12 | |||||
9-Day RSI | 32.67 | |||||
14-Day RSI | 56.99 | |||||
6-1 Month Momentum % | 47.83 | |||||
12-1 Month Momentum % | 25.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.5 | |||||
Quick Ratio | 1.1 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 357.67 | |||||
Days Sales Outstanding | 79.32 | |||||
Days Payable | 130.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 15.2 | |||||
3-Year Average Share Buyback Ratio | 2 | |||||
Shareholder Yield % | 0.19 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.83 | |||||
Operating Margin % | 47.3 | |||||
Net Margin % | 34.99 | |||||
EBITDA Margin % | 52.34 | |||||
FCF Margin % | 14.32 | |||||
OCF Margin % | 28.31 | |||||
ROE % | 109.36 | |||||
ROA % | 23.65 | |||||
ROIC % | 36.48 | |||||
3-Year ROIIC % | 35.59 | |||||
ROC (Joel Greenblatt) % | 105.61 | |||||
ROCE % | 50.64 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 40.81 | |||||
Forward PE Ratio | 24.88 | |||||
PE Ratio without NRI | 39.03 | |||||
Shiller PE Ratio | 125.23 | |||||
Price-to-Owner-Earnings | 81.5 | |||||
PEG Ratio | 1.28 | |||||
PS Ratio | 14.28 | |||||
PB Ratio | 32.9 | |||||
Price-to-Tangible-Book | 58.02 | |||||
Price-to-Free-Cash-Flow | 99.52 | |||||
Price-to-Operating-Cash-Flow | 50.38 | |||||
EV-to-EBIT | 29.7 | |||||
EV-to-Forward-EBIT | 34.04 | |||||
EV-to-EBITDA | 28.1 | |||||
EV-to-Forward-EBITDA | 31.31 | |||||
EV-to-Revenue | 14.71 | |||||
EV-to-Forward-Revenue | 13.09 | |||||
EV-to-FCF | 102.48 | |||||
Price-to-GF-Value | 0.8 | |||||
Price-to-Projected-FCF | 13.97 | |||||
Price-to-DCF (Earnings Based) | 1.12 | |||||
Price-to-DCF (FCF Based) | 4.84 | |||||
Price-to-Median-PS-Value | 1.84 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.56 | |||||
Price-to-Graham-Number | 10.03 | |||||
Earnings Yield (Greenblatt) % | 3.37 | |||||
FCF Yield % | 1.01 | |||||
Forward Rate of Return (Yacktman) % | 20.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 57,625.067 | ||
| EPS (TTM) (CHF) | 22.451 | ||
| Beta | -1.1494 | ||
| 3-Year Sharpe Ratio | 0.62 | ||
| 3-Year Sortino Ratio | 5.08 | ||
| Volatility % | 59.13 | ||
| 14-Day RSI | 56.99 | ||
| 14-Day ATR (CHF) | 0.043671 | ||
| 20-Day SMA (CHF) | 680 | ||
| 12-1 Month Momentum % | 25.93 | ||
| 52-Week Range (CHF) | 460 - 715 | ||
| Shares Outstanding (Mil) | 891.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eli Lilly and Co Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-04 10:00 | In 185 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-04 | In 184 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 10:00 | In 87 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 86 days | ||
| USD 1.730000 Cash Dividend | 2026-08-14 | In 10 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 10:00 | In 2 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 1 day | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 15:20 | 680.00 (+0.00%) | ||
| Investor event | 2026-06-06 18:00 | 680.00 (+0.00%) | ||
| USD 1.730000 Cash Dividend | 2026-05-15 | 680.00 (+0.00%) |
Show
Entries
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(LTS:0Q1G)'s stock price today?
The current price of LTS:0Q1G is CHF680.00. The 52 week high of LTS:0Q1G is CHF715.00 and 52 week low is CHF460.00.
When is next earnings date of Eli Lilly and Co(LTS:0Q1G)?
The next earnings date of Eli Lilly and Co(LTS:0Q1G) is 2026-08-05.
Does Eli Lilly and Co(LTS:0Q1G) pay dividends? If so, how much?
Eli Lilly and Co(LTS:0Q1G) does not pay dividend.
Press Release
Articles on Eli Lilly and Co
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers